Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Presentation EuroPCR 2023

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Presenter: Shigeru Saito

May 18, 2023

Presentation SOLACI 2016

Drug-eluting Stent and Dual Platelet Aggregation: What We Must Know

Presenter: Eduardo Nagib

June 09, 2016

Presentation ESC 2015

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Presenter: G?rard Helft

August 31, 2015

Presentation TCT 2014

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

Presenter: Giulio Stefanini

September 16, 2014

Presentation TCT 2014

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Dong Oh Kang

September 15, 2014

Presentation TCT 2014

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Antonio Colombo

September 15, 2014

Presentation TCT 2014

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

Presenter: Roxana Mehran, Harvey D. White, Nikolaus Sarafoff

September 15, 2014

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-7. Impact Of Early Versus Late Clopidogrel Discontinuation On Stent Thrombosis Following Percutaneous Coronary Intervention With First- And Second-Generation Drug-Eluting...

Presenter: Joshua Loh

October 29, 2013

Presentation TCT 2013

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Presenter: Salvatore Cassese, Robert Byrne, Tomohisa Tada, Lamin King, Adnan Kastrati

January 31, 2013

Presentation TCT 2013

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

Presenter: Laura Mauri, Gabriel Steg, Alexis Matteau, Edoardo Camenzind, Eric Boersma, Pascal Vranckx, Patrick Serruys, William O'Neill, Robert Yeh, William Wijns

January 31, 2013

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Presentation

Prolonged Clopidogrel Use After BMS and DES Placement: The VA Drug-Eluting Stent Study

Presenter: David P. Faxon

June 08, 2012

Presentation ACC 2012

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Presenter: Hyo-Soo Kim

March 24, 2012

Presentation TCT 2012

Stopping Clopidogrel 1 year After Drug-Eluting Stent (DES) Implantation: Is It Safe?

Presenter: Nalyaka Sambu, Hazel Dent, Timothy Warner, Nicola Englyst, Philip Leadbeater, Alex Hobson, Alison Calver, Simon Corbett, Huon Gray, Iain Simpson, John Morgan, Nick Curzen

January 03, 2012

Presentation TCT 2012

”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug Eluting Stents.”

Presenter: Andrzej Drewnicki, Maciej Lesiak, Malgorzata Pyda, Marek Grygier, Wlodzimierz Skorupski, Aleksander Araszkiewicz, Przemyslaw Mitkowski, Stefan Grajek

January 03, 2012

Advertisement

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Drug-eluting Stent and Dual Platelet Aggregation: What We Must Know

12 vs 48 months of dual antiplatelet therapy after drug-eluting stent placement: The OPTIDUAL Randomized Trial

Short-Duration Versus Guideline-Recommended 12-Month Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation

TCT 475: Triple Antithrombotic Therapy Versus Dual Antiplatelet Therapy in Patients with Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation

SECURITY: A Prospective, Randomized Trial of Six Months Versus 12 Months of Dual Antiplatelet Therapy Following Coronary Drug-Eluting Stent Implantation

ISAR-TRIPLE: A Prospective, Randomized Trial of Six Weeks Versus Six Months of Clopidogrel in Patients Treated with Concomitant Aspirin and Oral Anticoagulant Therapy Following Coronary Drug-Eluting Stent Implantation

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-7. Impact Of Early Versus Late Clopidogrel Discontinuation On Stent Thrombosis Following Percutaneous Coronary Intervention With First- And Second-Generation Drug-Eluting...

Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.

Individual and Regional Variations in Dual Antiplatelet Therapy Dose and Duration in a Large, Randomized International Trial Comparing Two Drug-eluting Stents: Results From...

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Prolonged Clopidogrel Use After BMS and DES Placement: The VA Drug-Eluting Stent Study

Adjunctive Cilostazol Versus Double Dose Clopidogrel After PCI with Drug Eluting Stent: The HOST-ASSURE Randomized Trial

Stopping Clopidogrel 1 year After Drug-Eluting Stent (DES) Implantation: Is It Safe?

”Safety of Dual Antiplatelet Therapy in Patients Treated with Coronary Drug Eluting Stents.”

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content